(14), the remarkable tumor uptake of [177Lu]Lu-rhPSMA-7.3 found in our preclinical experiments (13) could also be observed in patients (effective dose of 6.4 ± 6.7 mGy/MBq for [177Lu]Lu-rhPSMA-7.3 vs. 2.6 ± 2.4 mGy/MBq for [177Lu]Lu-PSMA I&T). Here, FOLH1 is linked to neoplasm.